High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
361.79M
+14.67%
1.093
+12.63%
369.95M
+14.13%
1.089
+31.21%
387.40M
+14.13%
1.198
+39.32%
Estimates Revision
The market is revising Upward the revenue expectations for Penumbra, Inc. (PEN) for FY2025, with the revenue forecasts being adjusted by 0.9% over the past three months. During the same period, the stock price has changed by 4.71%.
Revenue Estimates for FY2025
Revise Upward
+0.9%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.41%
In Past 3 Month
Stock Price
Go Up
+4.71%
In Past 3 Month
13 Analyst Rating
Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 307.92 USD with a low forecast of 266.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 294.720
Low
266.00
Averages
307.92
High
355.00
Current: 294.720
Low
266.00
Averages
307.92
High
355.00
JPMorgan
Robbie Marcus
Neutral
maintain
$265 -> $275
2025-11-06
Reason
JPMorgan
Robbie Marcus
Price Target
$265 -> $275
2025-11-06
maintain
Neutral
Reason
JPMorgan analyst Robbie Marcus raised the firm's price target on Penumbra to $275 from $265 and keeps a Neutral rating on the shares. The company reported a "beat and raise" quarter amid stroke market challenges, the analyst tells investors in a research note.
Canaccord
William Plovanic
Buy
maintain
$350 -> $355
2025-11-06
Reason
Canaccord
William Plovanic
Price Target
$350 -> $355
2025-11-06
maintain
Buy
Reason
Canaccord analyst William Plovanic raised the firm's price target on Penumbra to $355 from $350 and keeps a Buy rating on the shares. The firm said they had a very nice beat in Q3 fueled by its US Embo/Access, which benefited from the Ruby XL launch and the dedicated, focused salesforce created 1H/25.
Evercore ISI
Outperform
maintain
$285 -> $286
2025-11-06
Reason
Evercore ISI
Price Target
$285 -> $286
2025-11-06
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Penumbra to $286 from $285 and keeps an Outperform rating on the shares. The company's Q3 performance was a standout, beating Wall Street expectations across the board, the analyst tells investors in a research note. The firm added that strong growth in embolization and thrombectomy, coupled with a robust outlook, underscores a promising path forward.
Truist
Richard Newitter
Buy
downgrade
$310 -> $300
2025-10-15
Reason
Truist
Richard Newitter
Price Target
$310 -> $300
2025-10-15
downgrade
Buy
Reason
Truist analyst Richard Newitter lowered the firm's price target on Penumbra to $300 from $310 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects "healthy" Q3 revenue and earnings across its coverage but also braces for "stock volatility", with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on "cleaner" names where there is less perceived controversy heading into the quarter.
Wells Fargo
Overweight
initiated
$290
2025-10-01
Reason
Wells Fargo
Price Target
$290
2025-10-01
initiated
Overweight
Reason
Wells Fargo added Penumbra to the firm's Q4 2025 Tactical Ideas List. The firm says Penumbra has two important potential near-term catalysts, namely STORM-PE at TCT and VIVA; and FDA approval of Thunderbolt. Each has the potential to expand TAM, increase penetration and drive share gain, Wells adds. Penumbra management sounded positive on the second half of 2025 outlook. The firm has an Overweight rating on the name with a price target of $290 on the shares.
Evercore ISI
Outperform
initiated
$300
2025-09-02
Reason
Evercore ISI
Price Target
$300
2025-09-02
initiated
Outperform
Reason
Evercore ISI initiated coverage of Penumbra with an Outperform rating and $300 price target. As the "leading thrombectomy player" in the neurovascular segment, Penumbra is set to accelerate its topline growth heading into FY26 as China headwinds clear and new products launch, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Penumbra Inc (PEN.N) is 60.93, compared to its 5-year average forward P/E of 208.79. For a more detailed relative valuation and DCF analysis to assess Penumbra Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
208.79
Current PE
60.93
Overvalued PE
464.78
Undervalued PE
-47.21
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
93.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
154.17
Undervalued EV/EBITDA
33.32
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
8.72
Current PS
0.00
Overvalued PS
11.22
Undervalued PS
6.21
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
PEN News & Events
Events Timeline
(ET)
2025-11-05
16:24:47
Penumbra increases FY25 revenue forecast to $1.375B-$1.380B, up from $1.355B-$1.370B
2025-11-05
16:22:41
Penumbra announces Q3 non-GAAP EPS of 97 cents, surpassing consensus estimate of 92 cents.
2025-10-27 (ET)
2025-10-27
09:04:36
Penumbra announces favorable outcomes from embolism trial using vacuum thrombectomy
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/1d86b1dbcd5f6a1a8cf4de53a0691921200abac548fa517bd270a71889331302.png)
Preview
5.0
11-26Yahoo FinanceInsider at Penumbra Offloads Shares Valued at $2,179,212, Recent SEC Filing Reveals
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4c27cc3ff1de57db0ca44856ab54ca9d2470fbffe54f03017aca31795a45a9f2.png)
Preview
1.0
11-20PRnewswirePenumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0ed627587b59ba0b3eab09a080a5fbd5d7fedb16ff16fe4c4f20de5dfd33ebd5.png)
Preview
2.0
11-09BenzingaExpedia, Sandisk, and Penumbra Rank Among the Top 10 Large-Cap Winners Last Week (Nov. 3-Nov. 7): Is Your Portfolio Included?
Sign Up For More News
People Also Watch
FAQ
What is Penumbra Inc (PEN) stock price today?
What is Penumbra Inc (PEN)'s business?
What is the price predicton of PEN Stock?
What is Penumbra Inc (PEN)'s revenue for the last quarter?
What is Penumbra Inc (PEN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Penumbra Inc (PEN)'s fundamentals?
How many employees does Penumbra Inc (PEN). have?